AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy

Acute myeloid leukemia (AML) is an aggressive heterogeneous hematologic disease with high mortality in patients older than 60 years. Clinical studies have proven that combinations of FDA-approved Bcl-2 inhibitor, venetoclax and hypomethylating agents (HMA) are highly effective in elderly patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kyung Hee, Zhang, Weiguo, Basyal, Mahesh, Ostermann, Lauren, Fogler, William, Magnani, John, Andreeff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Submitted Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833936/
http://dx.doi.org/10.1016/S2152-2650(20)30760-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833936/
http://dx.doi.org/10.1016/S2152-2650(20)30760-6

Ejemplares similares